Literature DB >> 15856293

Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma.

Wael Swelam1, Hiroko Ida-Yonemochi, Satoshi Maruyama, Kazufumi Ohshiro, Jun Cheng, Takashi Saku.   

Abstract

To better understand the poorly vascularized background of the stroma of pleomorphic adenomas, we attempted to determine the expression of molecules related to blood vessels and hypoxic conditions in pleomorphic adenoma. Surgical specimens and tumor cells in primary culture of salivary pleomorphic adenomas were used for immunohistochemistry for CD31, vascular endothelial growth factor (VEGF) and its receptors Flk-1 and Flt-1, as well as for hypoxia markers, such as hypoxia-inducible factor-1alpha (HIF-1alpha) and lactate dehydrogenase-1 (LDH). At the same time, alternative splicing modes of the VEGF gene and expression levels of the HIF-1alpha gene were analyzed in surgical specimens by means of reverse-transcription polymerase chain reaction (RT-PCR) and direct sequencing of the PCR products. In addition to co-immunolocalization with CD31+ vascular endothelial cells, VEGF and its receptors were demonstrated in normal duct epithelial and myoepithelial cells as well as in tumor cells in ductal structures and in myxochondroid stromata. Immunolocalizations for HIF-1alpha and LDH were confirmed in the VEGF-positive area. Immunofluorescence signals for VEGF and others were confirmed in pleomorphic adenoma cells in culture. RT-PCR results showed that there were at least four splicing modes of the VEGF gene, among which VEGF(121) was most enhanced, and higher HIF-1alpha levels in pleomorphic adenomas. The results suggest that pleomorphic adenoma cells produce VEGF in several functional forms for their own proliferation or differentiation, and that the VEGF expression is controlled by hypoxic circumstances of poorly vascularized pleomorphic adenomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856293     DOI: 10.1007/s00428-005-1219-1

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  37 in total

1.  De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop.

Authors:  Z von Marschall; T Cramer; M Höcker; R Burde; T Plath; M Schirner; R Heidenreich; G Breier; E O Riecken; B Wiedenmann; S Rosewicz
Journal:  Gastroenterology       Date:  2000-11       Impact factor: 22.682

2.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

Authors:  N Ferrara; W J Henzel
Journal:  Biochem Biophys Res Commun       Date:  1989-06-15       Impact factor: 3.575

3.  Expression of vascular endothelial growth factor receptors in human prostate cancer.

Authors:  F A Ferrer; L J Miller; R Lindquist; P Kowalczyk; V P Laudone; P C Albertsen; D L Kreutzer
Journal:  Urology       Date:  1999-09       Impact factor: 2.649

4.  A potential autocrine role for vascular endothelial growth factor in prostate cancer.

Authors:  Michael W Jackson; James S Roberts; Susan E Heckford; Carmela Ricciardelli; Jurgen Stahl; Catherine Choong; David J Horsfall; Wayne D Tilley
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

5.  Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 AND KDR/Flk-1.

Authors:  Shoko Nishimura; Nobuaki Maeno; Katsuhiko Matsuo; Toshihiro Nakajima; Isao Kitajima; Hidehiko Saito; Ikuro Maruyama
Journal:  Cytokine       Date:  2002-05-21       Impact factor: 3.861

Review 6.  HIF at the crossroads between ischemia and carcinogenesis.

Authors:  Stefan A M Paul; Jonathan W Simons; Nicola J Mabjeesh
Journal:  J Cell Physiol       Date:  2004-07       Impact factor: 6.384

7.  Vascular endothelial growth factor in normal human salivary glands and saliva: a possible role in the maintenance of mucosal homeostasis.

Authors:  N S Taichman; A T Cruchley; L M Fletcher; E P Hagi-Pavli; E M Paleolog; W R Abrams; V Booth; R M Edwards; D Malamud
Journal:  Lab Invest       Date:  1998-07       Impact factor: 5.662

8.  VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Authors:  Tomohiko Usui; Susumu Ishida; Kenji Yamashiro; Yuichi Kaji; Vasiliki Poulaki; Johnny Moore; Tara Moore; Shiro Amano; Yoshitaka Horikawa; Darlene Dartt; Matthew Golding; David T Shima; Anthony P Adamis
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-02       Impact factor: 4.799

9.  Biosynthesis of basement membrane molecules by salivary adenoid cystic carcinoma cells: an immunofluorescence and confocal microscopic study.

Authors:  J Cheng; T Irié; R Munakata; S Kimura; H Nakamura; R G He; A R Lui; T Saku
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Regulation of vascular endothelial growth factor binding and activity by extracellular pH.

Authors:  Adrienne L Goerges; Matthew A Nugent
Journal:  J Biol Chem       Date:  2003-03-11       Impact factor: 5.157

View more
  10 in total

Review 1.  Functional Histology of Salivary Gland Pleomorphic Adenoma: An Appraisal.

Authors:  Asterios Triantafyllou; Lester D R Thompson; Kenneth O Devaney; Diana Bell; Jennifer L Hunt; Alessandra Rinaldo; Vincent Vander Poorten; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2014-11-08

2.  Neither expression of VEGF-C/D nor lymph vessel density supports lymphatic invasion as the mechanism responsible for local spread of recurrent salivary pleomorphic adenoma.

Authors:  R Salzman; I Stárek; L Kučerová; A Skálová; J Hoza
Journal:  Virchows Arch       Date:  2014-01       Impact factor: 4.064

3.  Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma.

Authors:  A B Soares; P B Juliano; V C Araujo; K Metze; A Altemani
Journal:  Virchows Arch       Date:  2007-06-26       Impact factor: 4.064

4.  Podoplanin is a novel myoepithelial cell marker in pleomorphic adenoma and other salivary gland tumors with myoepithelial differentiation.

Authors:  Masayuki Tsuneki; Satoshi Maruyama; Manabu Yamazaki; Ahmed Essa; Tatsuya Abé; Hamzah Ali Babkair; Md Shahidul Ahsan; Jun Cheng; Takashi Saku
Journal:  Virchows Arch       Date:  2012-12-22       Impact factor: 4.064

5.  Peptoid-based PET imaging of vascular endothelial growth factor receptor (VEGFR) expression.

Authors:  Guiyang Hao; Asghar Hajibeigi; Luis M De León-Rodríguez; Orhan K Oz; Xiankai Sun
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-08-01

6.  Carcinoma ex pleomorphic adenoma of the salivary glands: distinct clinicopathologic features and immunoprofiles between subgroups according to cellular differentiation.

Authors:  Jeong Won Kim; Gui Young Kwon; Jong-Lyel Roh; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim; Kyung-Ja Cho
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

7.  Immunohistochemical analysis of CD34 expression in salivary gland tumors.

Authors:  Saede Atarbashi Moghadam; Ayda Mohammad Abadi; Sepideh Mokhtari
Journal:  J Oral Maxillofac Pathol       Date:  2015 Jan-Apr

8.  Comparison of the blood and lymphatic microvessel density of pleomorphic adenoma and Basal cell adenoma.

Authors:  Andresa Borges Soares; Albina Altemani; Thais Ribeiro de Oliveira; Felipe de Oliveira Fonseca Rodrigues; Alfredo Ribeiro-Silva; Danilo Figueiredo Soave; Fabricio Passador-Santos; Suellen Trentin Brum; Marcelo Henrique Napimoga; Vera Cavalcanti de Araújo
Journal:  Clin Med Insights Pathol       Date:  2015-04-19

9.  Upregulation of serum vascular endothelial growth factor in patients with salivary gland tumor.

Authors:  Azadeh Andisheh Tadbir; Bijan Khademi; Mahyar Malekzadeh; Maryam Mardani; Bahar Khademi
Journal:  Patholog Res Int       Date:  2013-07-24

10.  Promising Gene Therapeutics for Salivary Gland Radiotoxicity.

Authors:  Renjith Parameswaran Nair; Gulshan Sunavala-Dossabhoy
Journal:  AIMS Med Sci       Date:  2016-11-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.